2.1 ARDS Definition, Pathophysiology & Phenotypes

Diagnostic Evolution and the Berlin Definition

Acute Respiratory Distress Syndrome (ARDS) was first described by Ashbaugh and colleagues in 1967 in a landmark case series of 12 intensive care patients exhibiting severe dyspnea, tachypnea, cyanosis refractory to supplemental oxygen, decreased static respiratory compliance, and diffuse alveolar infiltrates on chest radiography. In 1994, the American-European Consensus Conference (AECC) formalized diagnostic criteria, establishing categories for Acute Lung Injury (ALI; $\text{PaO}_2/\text{FiO}_2 \le 300\text{ mmHg}$) and ARDS ($\text{PaO}_2/\text{FiO}_2 \le 200\text{ mmHg}$). However, the AECC definition exhibited significant limitations: it lacked criteria for positive end-expiratory pressure (PEEP), relied on subjective interpretations of bilateral infiltrates, had undefined timing for "acute" onset, and mandated a pulmonary artery wedge pressure (PAWP) $\le 18\text{ mmHg}$ or the absence of left atrial hypertension, which overlooked the frequent clinical coexistence of left ventricular dysfunction or fluid overload with inflammatory lung injury.

To address these limitations, the European Society of Intensive Care Medicine convened an international panel in 2011, establishing the 2012 Berlin Definition. The Berlin definition retired the term "acute lung injury" and established four explicit, evidence-based diagnostic criteria:

1. Timing: Respiratory symptoms must originate within 1 week of a known clinical insult (e.g., severe sepsis, pneumonia, gastric aspiration, major trauma, pancreatitis) or represent new or worsening respiratory symptoms over the past 7 days.
2. Chest Imaging: Bilateral opacities visible on chest radiography or computed tomography (CT) that are not fully explained by pleural effusions, lobar or lung atelectasis, or pulmonary nodules.
3. Origin of Edema: Respiratory failure not fully explained by cardiac failure or fluid overload. An objective evaluation (e.g., transthoracic or transesophageal echocardiography, lung ultrasound, or invasive hemodynamic monitoring) is mandatory to exclude hydrostatic pulmonary edema if no clear ARDS risk factor is present.
4. Oxygenation Impairment: Arterial hypoxemia categorized while ventilated with a minimum PEEP or continuous positive airway pressure (CPAP) $\ge 5\text{ cmH}_2\text{O}$:

---

Pathophysiology and Histopathologic Phases

The morphological hallmark of ARDS is diffuse alveolar damage (DAD), which represents a coordinated, stereotypic response of pulmonary tissue to severe inflammatory insult. Histopathologically and clinically, ARDS evolves through three classically defined, overlapping phases:

1. The Exudative Phase (Days 0 to 7)

The exudative phase begins within hours of the inciting injury. Direct alveolar insults (e.g., gastric aspiration, bacterial or viral pneumonia) or indirect systemic inflammatory insults (e.g., sepsis, acute pancreatitis, severe burn injury, massive transfusion) activate resident alveolar macrophages and vascular endothelial cells. The release of pro-inflammatory cytokines (tumor necrosis factor-alpha [TNF-$\alpha$], interleukin-1-beta [IL-1$\beta$], interleukin-6 [IL-6], and interleukin-8 [IL-8]) stimulates extensive neutrophil marginization, activation, and migration across the alveolar-capillary membrane.

Neutrophils release cytotoxic granular enzymes, myeloperoxidase, reactive oxygen species, and neutrophil extracellular traps (NETs), severely disrupting the capillary endothelium and the tight junctions of type I alveolar epithelial cells. The resulting increase in vascular permeability leads to the flooding of interstitial spaces and alveoli with protein-rich exudative fluid, red blood cells, and cellular debris.

Two critical pathophysiological consequences emerge during this phase:

• Surfactant Depletion and Inactivation: Type II pneumocyte injury diminishes surfactant production, while intra-alveolar plasma proteins (particularly fibrinogen and monomeric fibrin) directly inactivate residual surfactant. This leads to dramatically increased surface tension, diffuse microatelectasis, and a severe right-to-left intrapulmonary shunt ($V_A/Q = 0$).
• Hyaline Membrane Formation: Denuded basement membranes become coated with dense, eosinophilic hyaline membranes composed of polymerized fibrin, condensed plasma proteins, and necrotic epithelial remnants. Gas diffusion is severely impaired, and static respiratory compliance ($C_{\text{rs}}$) drops precipitously.

2. The Proliferative Phase (Days 7 to 14)

The proliferative phase represents an early, coordinated attempt at tissue repair and restoration of barrier integrity. During this phase, surviving type II alveolar pneumocytes undergo vigorous cellular division, spreading over the denuded basal lamina and gradually differentiating into flat type I pneumocytes to re-establish the epithelial barrier. Type II cells actively express apical epithelial sodium channels (ENaC) and basolateral $\text{Na}^+/\text{K}^+$-ATPase pumps, creating an osmotic gradient that drives fluid reabsorption from the alveolar lumen back into the interstitial lymphatics.

Simultaneously, myofibroblasts and fibroblasts proliferate within the provisional fibrin scaffold, depositing fibronectin and early collagen. Neutrophilic infiltration recedes, replaced predominantly by mononuclear lymphocytes and macrophages that phagocytose cellular debris. Clinically, this phase is marked by dynamic heterogeneity: some patients experience progressive gas exchange improvement, radiographic clearing, and successful liberation from mechanical ventilation, whereas others transition toward unconstrained fibroproliferation.

3. The Fibrotic Phase (Day 14 and Beyond)

In patients who do not resolve the inflammatory cascade, extensive and dysregulated fibroproliferation leads to irreversible architectural remodeling. Intra-alveolar exudates organize into dense fibrous tissue, driven by sustained expression of transforming growth factor-beta (TGF-$\beta$) and platelet-derived growth factor (PDGF). Interstitial collagen deposition thickens alveolar septa, obliterating the normal microvascular architecture.

Microvascular thrombosis and progressive capillary obliteration lead to significant pulmonary hypertension, elevated right ventricular afterload, and markedly increased physiological dead space ($V_D/V_T$). Lung parenchyma develops patchy microcystic honeycombing and bullous emphysematous changes, rendering the lung stiff, highly non-compliant, and exceptionally prone to barotrauma. Patients in the fibrotic phase endure prolonged ventilator dependence and high late mortality.

---

ARDS Subphenotypes: Biological and Physiological

Recent clinical trials and physiological investigations demonstrate that ARDS is not a homogeneous syndrome, but rather a heterogeneous clinical collection of distinct subphenotypes requiring divergent clinical strategies.

Biological Subphenotypes: Hyperinflammatory vs. Hypoinflammatory

Through latent class analysis of large multicenter trial cohorts (ARMA, ALVEOLI, FACTT, SAILS, and the HARP-2 simvastatin trial), Calfee and colleagues identified two consistently distinct biological subphenotypes:

• Hyperinflammatory Subphenotype (~30% of patients):
  • Characterized by dramatically elevated plasma concentrations of inflammatory biomarkers, including IL-6, IL-8, TNF receptor-1 (TNFR-1), and soluble intercellular adhesion molecule-1 (ICAM-1).
  • Demonstrates lower serum bicarbonate, severe metabolic acidosis, significantly higher vasopressor requirements, and a higher prevalence of sepsis as the precipitating risk factor.
  • Carries a much higher 90-day mortality (~40-50%).
  • Therapeutic Responsiveness: In secondary analyses there was a significant subphenotype-by-treatment interaction: hyperinflammatory patients in ALVEOLI had lower mortality with higher PEEP, and in FACTT (Famous et al., 2017, as corrected) 90-day mortality was 40% with a conservative fluid strategy vs. 50% with a liberal one. These are hypothesis-generating findings, not yet a basis for treatment allocation.
• Hypoinflammatory Subphenotype (~70% of patients):
  • Characterized by lower systemic inflammatory markers, less endothelial activation, lower shock incidence, and higher serum bicarbonate.
  • Exhibits lower 90-day mortality (~20-25%).
  • Therapeutic Responsiveness: Hypoinflammatory patients derived no benefit from higher PEEP (with a signal toward harm), and in FACTT their 90-day mortality was 26% with conservative vs. 18% with liberal fluids.

Physiological / Morphological Subphenotypes: Type L vs. Type H

During the COVID-19 pandemic, Gattinoni and colleagues popularized the distinction between two physiological and radiological archetypes. The framework is debated (most patients fall on a continuum between the two), but it is a useful way to reason about recruitability in any ARDS:

• Type L (Low Elastance / High Compliance):
  • Characterized by low lung elastance (i.e., relatively preserved static respiratory system compliance, typically $C_{\text{rs}} > 50\text{ mL/cmH}_2\text{O}$).
  • CT imaging shows predominantly subpleural ground-glass opacities with minimal dense dependent consolidation ("low lung weight").
  • Low recruitability: Because non-aerated lung tissue is minimal, applying high PEEP does not recruit closed alveoli but instead overdistends already aerated units, causing dead-space expansion and right ventricular strain.
  • Severe hypoxemia is primarily mediated by vasoplegia and loss of hypoxic pulmonary vasoconstriction (HPV), resulting in perfusion of poorly ventilated lung regions.
• Type H (High Elastance / Low Compliance):
  • Characterized by high elastance (severe reduction in static compliance, typically $C_{\text{rs}} < 40\text{ mL/cmH}_2\text{O}$).
  • CT demonstrates dense, bilateral dependent consolidations ("high lung weight") with extensive edema.
  • High recruitability: Non-aerated, consolidated dependent units can be reopened with higher PEEP and prone positioning.
  • Represents the classic, fully expressed ARDS phenotype in which standard ARDSNet ventilation, higher PEEP, and early prone positioning are most clearly appropriate.

---

Clinical Traps and Differential Diagnosis

When evaluating acute bilateral pulmonary infiltrates and hypoxemic respiratory failure on the intensive care unit boards, clinicians must avoid critical diagnostic pitfalls:

1. Cardiogenic Pulmonary Edema vs. ARDS

Hydrostatic (cardiogenic) pulmonary edema and non-hydrostatic (permeability) pulmonary edema frequently share identical clinical presentations. Key distinguishing features include:

• Echocardiography / POCUS: ARDS classically demonstrates thickened, irregular pleural lines, subpleural consolidations, and non-homogeneous B-lines with interspersed "spared areas" of normal lung sliding. Cardiogenic pulmonary edema displays smooth, thin pleural lines, homogeneous and symmetric dependent B-lines ("lung rockets"), and preserved sliding without anterior consolidation.
• Left Atrial Filling Pressures: An elevated mitral $E/e'$ ratio ($> 14$), left atrial dilation, and elevated PAWP ($> 18\text{ mmHg}$) point toward a hydrostatic etiology. However, under the Berlin definition, the presence of left ventricular dysfunction or fluid overload does not rule out ARDS if an objective inflammatory insult (e.g., bacteremic sepsis, aspiration) is also present.

2. Transfusion-Related Acute Lung Injury (TRALI) vs. TACO

• TRALI: Occurs within 6 hours of blood product transfusion (most commonly plasma or platelets) mediated by donor anti-HLA or anti-HNA antibodies that bind recipient neutrophils sequestered in pulmonary capillaries. Characterized by acute permeability edema, normal left atrial pressures, low or normal BNP, and an edema fluid-to-plasma protein ratio of about $0.75$ or higher.
• TACO (Transfusion-Associated Circulatory Overload): Pure hydrostatic pulmonary edema resulting from rapid volume infusion in patients with compromised cardiovascular reserve. Features elevated central venous pressure, marked BNP elevation, left atrial enlargement, and an edema fluid-to-plasma protein ratio below about $0.65$, responding dramatically to diuresis.

3. Acute Eosinophilic Pneumonia (AEP)

Characterized by rapid-onset febrile hypoxemic respiratory failure, diffuse alveolar infiltrates, and absence of peripheral eosinophilia on initial presentation. A history of recent initiation or change in smoking habits (cigarettes, vaping) is classic. Definitive diagnosis requires bronchoalveolar lavage (BAL) demonstrating $\ge 25\%$ eosinophils. It responds promptly to systemic corticosteroids.